Referring back to the NIH statement on ivermectin:
"Although there have been many ivermectin studies, only a few trials have been adequately powered, well-designed, and well-conducted (emphasis added). More recent clinical trials address the limitations of earlier studies but fail to show clear evidence that ivermectin reduces time to recovery or prevents COVID-19 disease progression (emphasis added). For this reason, and because several medications now have demonstrated clinical benefit for the treatment of COVID-19, the Panel recommends against the use of ivermectin for the treatment of COVID-19, except in a clinical trial (AIIa). Additional adequately powered, well-designed, and well- conducted trials are needed to evaluate the effect of ivermectin on COVID-19. "